Let The Games Begin: Celltrion Sets Sights On Global Markets After Approval Of Remicade Biosimilar In Korea
This article was originally published in PharmAsia News
In addition to Remicade, Celltrion has seven other biosimilars in development, including versions of Roche’s MabThera and Herceptin.
You may also be interested in...
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
SEOUL - Merck & Co. has become a leader in the race to bring a low-cost version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept) to the market after gaining rights to a late-stage biosimilar version of the biologic developed by South Korea's Hanwha Chemical Corporation
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.